The inhibition of RIPK1 was recently implicated to ameliorate NASH pathologic characteristics in HFD-fed mice and to reverse steatosis development through the MLKL-mediated pathway [51]. The gene discussed is RIPK1; the disease is metabolic dysfunction-associated steatohepatitis.